- Autor
-
Pracoviště
Clinic of Professional Pathology Sara... 1 Clinical Development Oncology Amgen I... 1 Department of Hematology Ankara Unive... 1 Department of Internal Medicine Hemat... 1 Department of Internal Medicine Niiga... 1 Department of Internal Medicine Seoul... 1 Epworth Healthcare and Sir Peter MacC... 1 Global Biostatistical Science Amgen I... 1 Hematology and Medical Oncology Depar... 1 Hematology and Oncology Janssen Resea... 1 Institut Català d'Oncologia and Josep... 1 John Theurer Cancer Center Hackensack... 1 Service d'Hématologie et Thérapie cel... 1 Tisch Cancer Institute Icahn School o... 1
- Formát
- Publikační typ
- Check Tag
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
- Autor
-
Pracoviště
Clinic of Professional Pathology Sara... 1 Clinical Development Oncology Amgen I... 1 Department of Hematology Ankara Unive... 1 Department of Internal Medicine Hemat... 1 Department of Internal Medicine Niiga... 1 Department of Internal Medicine Seoul... 1 Epworth Healthcare and Sir Peter MacC... 1 Global Biostatistical Science Amgen I... 1 Hematology and Medical Oncology Depar... 1 Hematology and Oncology Janssen Resea... 1 Institut Català d'Oncologia and Josep... 1 John Theurer Cancer Center Hackensack... 1 Service d'Hématologie et Thérapie cel... 1 Tisch Cancer Institute Icahn School o... 1
- Formát
- Publikační typ
- Check Tag
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
NLK
Medline Complete (EBSCOhost)
od 1998-01-01 do Před 1 rokem
PubMed
33112184
DOI
10.1080/10428194.2020.1832672
Knihovny.cz E-zdroje
The regimen of carfilzomib, daratumumab, and dexamethasone (KdD) shows activity in patients with relapsed/refractory multiple myeloma. KdD at the twice-weekly 56 mg/m2 carfilzomib dose (KdD56) was used in the randomized phase 3 CANDOR study (NCT03158688), whereas KdD at the once-weekly 70 mg/m2 carfilzomib dose (KdD70) was used in the phase 1 b EQUULEUS study (NCT01998971). We analyzed efficacy data from comparable CANDOR and EQUULEUS patients using inverse probability of treatment weighting (IPTW)-adjusted models. These weights were calculated from propensity scores derived to balance prespecified baseline covariates. The side-by-side and adjusted comparisons showed similar efficacy for overall response rates and progression-free survival in the two groups, with a series of sensitivity analyses showing consistent findings. Safety data were generally consistent with the known safety profiles of each individual drug. Once-weekly KdD70 is comparable to twice-weekly KdD56 in terms of efficacy and safety while being a more convenient dosing option.
- MeSH
- dexamethason terapeutické užití MeSH
- lidé MeSH
- mnohočetný myelom * farmakoterapie MeSH
- monoklonální protilátky MeSH
- oligopeptidy škodlivé účinky MeSH
- protokoly antitumorózní kombinované chemoterapie * škodlivé účinky MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Sdílet
Název dokumentu
Po ukončení testovacího provozu bude odkaz přesměrován adresu produkční verze portálu Medvik.